Compare Neurocrine Biosciences Inc (NBIX) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Ross Stores, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Ross Stores, Inc. trades at $234 (market cap $75.63B). The key difference: Ross Stores, Inc. is far larger — about 4.3× Neurocrine Biosciences Inc's market cap, and Ross Stores, Inc. pays a 0.75% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | ROST | |
|---|---|---|
Market Cap | $17.40B | $75.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $240.13 |
52-Week Low | $123.10 | $134.02 |
Enterprise Value | $16.49B | $76.23B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Ross Stores (ROST) trades at $235.78, up 1.05% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong Q1 2026 results with 21% sales growth and expanding margins, while expanding its store footprint with 47 new locations in mid-2026. Valuation metrics show a P/E of 32.93 and robust profitability with a 38.98% ROE, though the stock trades near analyst price targets.
The outlook remains positive due to consistent earnings outperformance and store expansion, but risks include high valuation multiples and competitive retail pressures. Analyst consensus is bullish with a $259 price target, suggesting moderate upside potential from current levels amid broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
